Nā huahana

ʻIke ʻia nā polycations ma ke ʻano he mea lawe e hoʻopuka i nā waikawa nucleic therapeutic.ʻO ka polycations he lāʻau lapaʻau inert maʻamau me ka hana hoʻokahi o ka lawe ʻana i nā ukana therapeutic.Hōʻike kēia haʻawina i ka synthesis o kahi polycation self-immolative (DSS-BEN) e pili ana i kahi lāʻau analogue polyamine N (1), N (11) -bisethylnorspermine (BENSpm).Ua hoʻolālā ʻia ka polycation e hana pālua ma ke ʻano he lawe lawe gene a me kahi prodrug e kuhikuhi ana i ka dysregulated polyamine metabolism i ka maʻi kanesa.Ke hoʻohana nei i ka hui pū ʻana o NMR a me HPLC, hōʻoia mākou i ka polycation self-immolative e hana i ka degradation intracellular i loko o ka lāʻau makua BENSpm.ʻO ka BENSpm i hoʻokuʻu ʻia e hoʻopau i nā pae kelepona o ka spermidine a me ka spermine a hoʻoponopono i nā enzyme catabolic polyamine spermine/spermidine N(1)-acetyltransferase (SSAT) a me spermine oxidase (SMO).Hoʻokumu nā polycations synthesized i nā polyplexes me DNA a hoʻomaʻamaʻa i ka hoʻololi kūpono.ʻO ka hoʻohana ʻana i ka hiki o BENSpm ke hoʻomaopopo i nā pūnaewele maʻi maʻi i TNFα-induced apoptos, hōʻike mākou i ka DSS-BEN e hoʻonui i ka hana pepehi cell o TNFα gene therapy.ʻO nā ʻike i hōʻike ʻia e hōʻoia i ka DSS-BEN ma ke ʻano he ʻōnaehana hāʻawi lua-hana e hiki ai ke hoʻopuka i kahi gene therapeutic a hoʻomaikaʻi i ka hopena o ka gene therapy ma muli o ka hoʻohaʻahaʻa intracellular o DSS-BEN i BENSpm a me ka hopena maikaʻi o BENSpm ma ka polyamine dysregulated. metabolism i ka maʻi kanesa.